文献速递消化道肿瘤与早癌消化内镜

巴雷特肿瘤内镜根除治疗成功后非相关死亡的发生率与预测

Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett's Neoplasia.
PubMed 文献 · Gastroenterology · 2024-03-04

该研究基于荷兰全国巴雷特注册队列,纳入1154例内镜根除治疗(EET)成功的巴雷特肿瘤患者,随访中位59个月(总6375人年),154例(13%)死于非食管腺癌(EAC)原因,非EAC死亡年死亡率为24.1/1000人年(95%CI 20.5-28.2),EAC相关死亡仅4例(年死亡率0.5/1000人年,95%CI 0.1-1.4);非EAC死亡风险是EAC相关死亡风险的48倍(95%CI 15-99)。Charlson共病指数(CCI)对长期死亡预测判别力良好(一致性统计量0.78,95%CI 0.72-0.84),校准尚可。

要点

  • EET成功后非EAC死亡年死亡率为24.1/1000人年,EAC相关死亡仅0.5/1000人年。
  • 非EAC死亡风险是EAC相关死亡的48倍(95%CI 15-99)。
  • CCI对EET后长期死亡预测判别力良好(一致性统计量0.78)。

核心结论

  • EET成功后非EAC死亡风险是EAC相关死亡风险的48倍(95%CI 15-99)。
  • 年轻(<71岁)EET后患者与一般荷兰人群相比预期寿命显著降低。
  • CCI对EET后长期死亡具有较强预测能力,可辅助个体化随访决策,包括合适的终止时机。

研究设计与样本

  • 基于荷兰全国巴雷特注册队列,纳入所有EET成功的巴雷特肿瘤患者1154例,平均年龄64岁(±9)。
  • 数据与荷兰国家统计数据库合并以获取准确死亡数据。
  • 评估年死亡率(每1000人年)和其他原因死亡的标准死亡比,并通过判别力和校准评估CCI表现。

主要发现

  • 随访中位59个月(p25-p75 37-91;总6375人年),154例(13%)死于非EAC原因。
  • 非EAC死亡原因最常见为非EAC癌症(n=58)、心血管疾病(n=31)和肺部疾病(n=26)。
  • 非EAC死亡年死亡率为24.1(95%CI 20.5-28.2);EAC相关死亡4例,年死亡率为0.5(95%CI 0.1-1.4)。
  • 与一般荷兰人群相比,最低3个年龄四分位组(即年龄<71岁)患者死亡率显著升高。
  • CCI验证显示判别力良好(一致性统计量0.78;95%CI 0.72-0.84),校准尚可。

关键数值与推荐

  • 非EAC死亡年死亡率为24.1/1000人年(95%CI 20.5-28.2)。
  • EAC相关死亡年死亡率为0.5/1000人年(95%CI 0.1-1.4)。
  • 非EAC死亡风险是EAC相关死亡风险的48倍(95%CI 15-99)。
  • CCI一致性统计量为0.78(95%CI 0.72-0.84)。

临床怎么用

  • 作者认为,CCI这一简易评分系统可辅助EET后个体化随访决策,包括合适的终止时机。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Follow-up (FU) strategies after endoscopic eradication therapy (EET) for Barrett's neoplasia do not consider the risk of mortality from causes other than esophageal adenocarcinoma (EAC). We aimed to evaluate this risk during long-term FU, and to assess whether the Charlson Comorbidity Index (CCI) can predict mortality. METHODS: We included all patients with successful EET from the nationwide Barrett registry in the Netherlands. Data were merged with National Statistics for accurate mortality data. We evaluated annual mortality rates (AMRs, per 1000 person-years) and standardized mortality ratio for other-cause mortality. Performance of the CCI was evaluated by discrimination and calibration. RESULTS: We included 1154 patients with a mean age of 64 years (±9). During median 59 months (p25-p75 37-91; total 6375 person-years), 154 patients (13%) died from other causes than EAC (AMR, 24.1; 95% CI, 20.5-28.2), most commonly non-EAC cancers (n = 58), cardiovascular (n = 31), or pulmonary diseases (n = 26). Four patients died from recurrent EAC (AMR, 0.5; 95% CI, 0.1-1.4). Compared with the general Dutch population, mortality was significantly increased for patients in the lowest 3 age quartiles (ie, age <71 years). Validation of CCI in our population showed good discrimination (Concordance statistic, 0.78; 95% CI, 0.72-0.84) and fair calibration. CONCLUSION: The other-cause mortality risk after successful EET was more than 40 times higher (48; 95% CI, 15-99) than the risk of EAC-related mortality. Our findings reveal that younger post-EET patients exhibit a significantly reduced life expectancy when compared with the general population. Furthermore, they emphasize the strong predictive ability of CCI for long-term mortality after EET. This straightforward scoring system can inform decisions regarding personalized FU, including appropriate cessation timing. (NL7039).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. van Munster SN, Verheij EPD, Ozdemir Ö, et al. Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett's Neoplasia. Gastroenterology. 2024. PMID: 38447738. doi:10.1053/j.gastro.2024.02.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。